Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients

被引:55
|
作者
Kawano, Yoshihiko [1 ]
Suzuki, Michio [1 ]
Kawada, Jun-ichi [1 ]
Kimura, Hiroshi [2 ]
Kamei, Hideya [3 ]
Ohnishi, Yasuharu [3 ]
Ono, Yasuyuki [4 ]
Uchida, Hiroo [4 ]
Ogura, Yasuhiro [3 ]
Ito, Yoshinori [1 ]
机构
[1] Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Virol, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Grad Sch Med, Dept Transplantat Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Pediat Surg, Showa Ku, Nagoya, Aichi 4668550, Japan
关键词
Immunization; Live-attenuated vaccine; Inactivated vaccine; Children; Liver transplantation; VARICELLA INFECTION; HUMORAL IMMUNOGENICITY; VIRUS VACCINE; ZOSTER; MEASLES;
D O I
10.1016/j.vaccine.2015.01.075
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Liver transplantation recipients are at high risk for severe complications due to infections because of being treated with immunosuppressive drugs that affect the immune system. Vaccination for liver transplantation candidates is generally recommended before surgery, but the opportunities for vaccination prior to transplantation in pediatric candidates are often limited by severe disease conditions. Methods: The participants in this study comprised 39 pediatric recipients of living donor liver transplantation performed between 2005 and 2013. Criteria for administering live-attenuated (measles, rubella, mumps, and varicella) and inactivated (hepatitis B, pertussis, and Japanese encephalitis) vaccines were as follows; (1) >1 year after transplantation; (2) no use of systemic steroids to treat acute rejection within the last 6 months; (3) serum trough concentration of tacrolimus <5 ng/mL; (4) no severe immunosuppression according to blood examinations; and (5) provision of written informed consent. Median age at transplantation was 17 months, and median period from transplantation to the beginning of immunization was 18 months. Results: Seroprotection rates for measles, rubella, mumps, varicella, hepatitis B, pertussis, and Japanese encephalitis after post-transplant immunization were 44% (11/25), 70% (19/27), 48% (12/25), 32% (6/19), 83% (19/23), 87% (13/15), and 88% (7/8), respectively. Seroprotection rates for measles, rubella, mumps, and varicella after second vaccination for recipients with primary vaccine failure after first vaccination were 100% (8/8), 50% (1/2), 71% (5/7), and 50% (5/10), respectively. While four recipients contracted mumps and eight contracted varicella before immunization, one recipient developed varicella after immunization. No serious systemic adverse events were observed in vaccinated recipients. Conclusions: Seroprotection rates for measles, mumps, and varicella appeared low in children after the first post-transplantation vaccination. Immunizations with four live-attenuated and three inactivated vaccines were safe and effective for pediatric liver transplantation recipients who were not severely immunosuppressed. (C) 2015 Published by Elsevier Ltd.
引用
收藏
页码:1440 / 1445
页数:6
相关论文
共 50 条
  • [41] THE EFFECTIVENESS OF SIMULTANEOUS IMMUNIZATION AGAINST INFLUENZA WITH LIVE AND INACTIVATED VACCINES, 1980-1983
    ZHILOVA, GP
    IGNATYEVA, GS
    ORLOV, VA
    MALIKOVA, EV
    MAKSAKOVA, VL
    EFREMOV, BV
    RUDENKO, LG
    IKRAMOV, NB
    KARACHEVTSEV, AP
    KOZHUKHOV, VM
    SHADRIN, AS
    SMORODINTSEV, AA
    VOPROSY VIRUSOLOGII, 1986, (01) : 40 - 44
  • [42] Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines
    Sealy, Robert
    Webby, Richard J.
    Crumpton, Jeri C.
    Hurwitz, Julia L.
    INTERNATIONAL IMMUNOLOGY, 2013, 25 (03) : 183 - 195
  • [43] Comparative Efficacy of Inactivated and Live Attenuated Influenza Vaccines
    Monto, Arnold S.
    Ohmit, Suzanne E.
    Petrie, Joshua G.
    Johnson, Emileigh
    Truscon, Rachel
    Teich, Esther
    Rotthoff, Judy
    Boulton, Matthew
    Victor, John C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13): : 1260 - 1267
  • [44] Live Attenuated and Inactivated Influenza Vaccine Effectiveness
    Chung, Jessie R.
    Flannery, Brendan
    Ambrose, Christopher S.
    Begue, Rodolfo E.
    Caspard, Herve
    DeMarcus, Laurie
    Fowlkes, Ashley L.
    Kersellius, Geeta
    Steffens, Andrea
    Fry, Alicia M.
    PEDIATRICS, 2019, 143 (02)
  • [45] Alternative methods to compare safety of live-attenuated respiratory Newcastle disease vaccines in young chicks
    Malo, Aris
    de Wit, Sjaak
    Swart, Wim A. J. M.
    Cook, Jane K. A.
    VETERINARY RECORD, 2017, 181 (09) : 236 - +
  • [46] Clinical outcomes and safety of live-attenuated vaccines in children exposed to biologics response modifiers in utero
    Zerbo, Ousseny
    Goddard, Kristin
    Lewis, Edwin
    Getahun, Darios
    Palmsten, Kristin
    Fuller, Candace C.
    Crane, Bradley
    Donahue, James
    Daley, Matthew F.
    Jackson, Lisa A.
    Klein, Nicola
    Modaressi, Shararareh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 482 - 482
  • [47] Safety and immunogenicity of the live-attenuated varicella vaccine in pediatric solid organ transplant recipients: A systematic review and meta-analysis
    Piche-Renaud, Pierre-Philippe
    Lee, Erika Yue
    Ji, Catherine
    Huang, Jenny Yu Qing
    Uleryk, Elizabeth
    Teoh, Chia Wei
    Morris, Shaun K.
    Top, Karina A.
    Upton, Julia E. M.
    Vyas, Manav V.
    Allen, Upton D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2023, 23 (11) : 1757 - 1770
  • [48] Rational Design of Live-Attenuated Vaccines against GenomeReduced Pathogens
    Nishikawa, Sayaka
    Ogawa, Yohsuke
    Shiraiwa, Kazumasa
    Nozawa, Rieko
    Nakayama, Momoko
    Eguchi, Masahiro
    Shimoji, Yoshihiro
    MICROBIOLOGY SPECTRUM, 2022, 10 (06):
  • [49] Development of Live-Attenuated Arenavirus Vaccines Based on Codon Deoptimization
    Cheng, Benson Yee Hin
    Ortiz-Riano, Emilio
    Nogales, Aitor
    de la Torre, Juan Carlos
    Martinez-Sobrido, Luis
    JOURNAL OF VIROLOGY, 2015, 89 (07) : 3523 - 3533
  • [50] Live-attenuated HIV vaccines: How safe is safe enough?
    Michael Murphey-Corb
    Nature Medicine, 1997, 3 : 17 - 18